MYL News and Press, Mylan N.V. From 06/18/20

Upjohn Inc. (“Newco”), a wholly-owned subsidiary of Pfizer Inc. (“Pfizer”) (NYSE: PFE), Upjohn Finance B.V. (“Finco”), a wholly-owned subsidiary of Newco, Pfizer and Mylan N.V. (“Mylan”) (Nasdaq: MYL) today announced the pricing of a pri...

The U.S. Food and Drug Administration on Monday revoked its emergency use authorization (EUA) for chloroquine phosphate and hydroxychloroquine sulfate to be used as treatments for COVID-19. FDA Chief Scientist Denise M. Hinton wrote that the evidence does not reasonably suggest that the drugs ar...

Mylan N.V. (NASDAQ: MYL ) will invest additional $20M in support of continued Phase 3 study of Glatiramer Acetate (GA) Depot, a proposed once-monthly injection for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). More news on: Mylan, Inc., Healthcare stocks n...

NESS ZIONA, Israel, June 15, 2020 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a privately held, fully integrated, late clinical stage biopharmaceutical company today announced an additional $20 million investment from Mylan in support of continued Phase 3 clinical study progress to bring to marke...

Here's some welcome news for diabetics dealing with the high price of insulin : The Food and Drug Administration has approved Mylan (NASDAQ: MYL) and Biocon's Semglee, which is essentially identical to Sanofi 's (NASDAQ: SNY) insulin product Lantus. The companies didn't disclose what ...

HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India , June 11, 2020 /PRNewswire/ --  Mylan N.V.  (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (ND...

Biogen (NASDAQ: BIIB) has taken its shareholders on a roller-coaster ride over the past year or so, and more potential trouble is on the horizon for the biotech. Given that, now may be a good time for shareholders to consider jumping ship -- at least, so says Bernstein analyst Aaron Gal. Ga...

A coalition of 51 attorneys general in the U.S. has filed an antitrust complaint  in federal court against 26 companies making generic dermatology drugs and 10 executives at these firms claiming wide-spread price-fixing, marketing allocating and bid-rigging related to over 80 different...

Many generic drug makers began the year with a strong start after a dismal performance in 2019. The recent market plunge from the COVID-19 pandemic caused many pharmaceutical stocks to lose decent portions of their market values. Despite a broad market recovery, some of these stocks are stil...

Since the local market bottom on March 23rd, 2020, the S&P 500 ( SPY ) has rallied a remarkable 43%. The gains have not all come from the megacaps. A version of the S&P 500 that equal-weights the constituents ( RSP ) has done even better, rallying roughly 54%. Source: Bloomberg The...